Category Archives: PrEP

Thai trial yield continues with news vaccine changed virus

By on .

The vaccine that showed a vaccine can prevent HIV infection also has shown that the vaccine changed the virus in people who did become infected, according to research revealed today in the first plenary session of AIDS Vaccine 2012. The findings were the third revelation from a study that first generated excitement in the AIDS […]

Sustainable HIV prevention possibilities present choices, challenges

By on .

When he looks at what biomedical science can do in the next decade to prevent HIV transmission, Jim Turpin of the National Institutes of Health said, he thinks of the lyrics of a Timbuk3 song: “The future’s so bright I gotta wear shades.” By, which, actually, he means — don’t get blinded by the light; […]

Paths to a cure: Dr. Dan Kuritzkes discusses experiences of two patients

By on .

When Dr. Dan Kuritzkes of Harvard Medical School and Brigham and Women’s Hospital presented his team’s findings on two HIV-positive men who remained on antiretroviral therapy while undergoing stem cell transplants, and in whom the levels of HIV DNA had since dropped to undetectable levels, he was careful to emphasize that he was not claiming […]

CDC issues interim guidelines on preexposure antiretroviral use for heterosexual adults

By on .

The Centers for Disease Control and Prevention has released guidelines for clinicians prescribing antiretroviral medicine to prevent acquisition of HIV in heterosexual men and women, saying daily doses of Truvada can be safe and effective in reducing risk of infection. The guidelines, released in the agency’s August 10 Morbidity and Mortality Weekly Report, emphasize that […]

Breaking News: Truvada approved to help protect uninfected from HIV

By on .

The U.S. Food and Drug Administration has approved the antiretroviral drug Truvada, to be used as a preexposure preventive measure by people who, uninfected, may be exposed to the virus through HIV-positive partners. The drug previously was approved to treat people living with HIV. As a preventive measure the drug would be taken daily, by […]

Is PrEP Ready for Primetime?

By on .

This week’s New England Journal of Medicine showcases the results of clinical trials testing the use of antiretroviral drugs to prevent HIV acquisition in uninfected individuals.  The results, which have been widely reported at major conferences, are mixed. An article by Lut Van Damme and colleagues reports on the primary results of the Preexposure Prophylaxis […]

Beginning to End the AIDS Epidemic: What’s the Research Agenda?

By on .

Capitol Hill briefing highlights research agenda to end AIDS

The following is a guest blog post by Chris Collins, vice president and director of Public Policy at the Foundation for AIDS Research (amfAR) and Mitchell Warren, executive director of AVAC.

Looking back over three decades of AIDS, it’s hard to point to a better investment than research. Over the past three years, a string of HIV prevention research breakthroughs has put the ambitious goal of even talking about an end of AIDS within sight for the first time. With more strategic use of the tools we have today, we can bend the curve of new infections…

Updated: FDA committee recommends Truvada’s approval as PrEP

By on .

The U.S. Food and Drug Administration (FDA) Antiviral Drugs Advisory Committee recommended Thursday that the supplemental application for Gilead Sciences’ HIV drug Truvada (a combination of emtricitabine plus tenofovir, or TDF-FTC) as pre-exposure prophylaxis (PrEP) be approved for high-risk, HIV-negative individuals to reduce the risk of sexually acquired HIV infection. The panel of medical experts, […]

AIDS-Free Generation may remain elusive goal

By on .

Dr. Dorothy Mbori-Ngacha from UNICEF presented a sobering picture of the potential to eliminate 90 percent of HIV infections among children by 2015—the goal established by UNAIDS and the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) program in June of 2011.  She outlined the four pillars of the achieving that goal at the 19th […]

Poor adherence stopped study of PrEP in women

By on .

The following is a guest blog post by HIV Medicine Association Executive Director, Andrea Weddle, who is live blogging from the 19th Conference on Retroviruses and Opportunistic Infections in Seattle. Data presented from the FEM-PrEP trial by Dr. Lut Van Damme Tuesday highlighted the challenge that adherence plays in successfully deploying effective Pre-Exposure Prophylaxis (PrEP) […]